Telomere Diagnostics Successfully Enforces TeloYears Patents

Published: Sep 26, 2017

Sales of Titanovo Tests That Infringed on Patents and Lacked Appropriate Validation Cease

MENLO PARK, Calif.--(BUSINESS WIRE)--Telomere Diagnostics has successfully resolved the lawsuit it brought to prevent Titanovo from using the patented technology behind the TeloYears™ genetic test for cellular age. In response to the lawsuit, Titanovo has taken down its website and ceased all sales and distribution of all of its products and services.

The patented TeloYears™ test made by Telomere Diagnostics measures telomere length, a recognized biomarker for aging well. Telomere Diagnostics has invested substantial resources over the years to ensure reliable and repeatable results from TeloYears™ based upon certified laboratory testing. TeloYears™ is the world’s only telomere lab whose analytical validation of its measurement method has been published in a peer-reviewed scientific journal.

Telomere Diagnostics discovered Titanovo’s patent infringement upon receiving press reports in April and May of this year contrasting their different test results. Telomere Diagnostics’ investigation revealed efforts by Titanovo to take advantage of the public’s interest in DNA testing products by rushing to market a test that not only copied the TeloYears™ patent, but also generated test results that lacked appropriate validation and certification. As alleged in the lawsuit, the inferior Titanovo results were unfairly tarnishing the reputation of legitimate providers of telomere measurement products and services such as Telomere Diagnostics.

“We are deeply committed to providing consumers with a scientifically valid method for measuring the length of their telomeres,” said Telomere Diagnostics CEO Jason Shelton. “Protecting against the unauthorized use of our patented technology by companies that do not share our commitment to ensuring that the test results can be trusted as a lens on whether a person is aging well, is most importantly a win for our consumers.”

Having caused Titanovo to shut down all competing operations, Telomere Diagnostics has today withdrawn its lawsuit but has the ability to renew the litigation should Titanovo attempt to re-enter the market.

About Telomere Diagnostics

Telomere Diagnostics, Inc. is a privately held molecular testing company founded in 2010 by four scientists, including the winner of the Nobel Prize in Medicine in 2009 for pioneering work in telomere biology. Its lab in Silicon Valley, California, is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. The company measures parts of chromosomes called telomeres, the protective caps on the ends of DNA strands that shorten with age, using its proprietary quantitative polymerase chain reaction (qPCR) assay, the world’s leading method of measuring Average Telomere Length (ATL). Beyond TeloYears, the company is actively developing other potential uses of ATL to address unmet clinical needs in cardiovascular disease, oncology and reproductive health.

To learn more about the TeloYears genetic test, please visit https://www.teloyears.com.

The TeloYears test is not intended for screening, diagnosing, treating or preventing diseases or medical conditions. The test is available for individuals between the ages of 20 to 80 within the United States, except for the state of New York.

The information provided by the TeloYears test should not be used to replace medically appropriate screening tests recommended based upon actual age or other risk factors, nor should the information be used to make decisions about diagnosis or treatment of diseases or medical conditions. The Telomere Diagnostics lab is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical testing. The performance characteristics of this test were determined by Telomere Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration.

Test reports are kept absolutely private according to our Privacy Policy and are available only in a fashion that maintains compliance with the HIPAA security rule, which regulates privacy and security of health information.

DGI Comm
Susan Forman/Laura Radocaj, 212-825-3210

Back to news